One study examines the small molecular cardiac myosin inhibitor for safety and efficacy at 96 weeks, and another compares it ...

At World Sleep 2025, a discussion group examined the emerging role of GLP-1 receptor agonists in obstructive sleep apnea (OSA ...

Placebo-subtracted mean weight loss up to 14.1%after 28 weeks with no plateauPotential for best-in-class tolerability with minimal diarrhea ...

Ladies and gentlemen, greetings, and welcome to MBX Biosciences Conference Call. Today's call is being recorded. [Operator Instructions] As a reminder, this conference is being recorded. It is now my ...

Working together as a team to better communicate between physicians and nurses as well as the complete caregiving team will ...

Viking Therapeutics targets obesity and MASH with high-risk prospects, trial concerns, and strong funding, but lags leaders ...

By seeing yourself with grace, you create an internal safe space where you can grow. You can love your shadow and feel unconditional love, When you have your own back, you’ll feel braver to take the ...

Bayer announced today that data from across the KERENDIA ® (finerenone) comprehensive clinical trial program will be presented at the Heart Failure Society of America (HFSA)’s Annual Scientific ...

VIENNA — Tirzepatide was associated with improvements in body weight and body composition, and with lower insulin doses, in the first-ever randomized controlled trial (RCT) of the drug in people with ...

Approved for earliest symptomatic stages of disease, demonstrating significant slowing of cognitive and functional decline Only therapy with evidence to ...

European Commission grants marketing authorization to Lilly's Kisunla to treat early symptomatic Alzheimer's disease: Indianapolis Saturday, September 27, 2025, 09:00 Hrs [IST] El ...

Indianapolis: Eli Lilly and Company has announced that the European Commission (EC) has granted marketing authorization for ...